Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2025-10-24 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司总经理工作细则（2025年10月）
Governance Information Classification · 95% confidence The document is titled '总经理工作细则' which translates to 'General Manager Work Rules' or 'General Manager Operating Procedures' for 江苏四环生物股份有限公司. It details the duties, responsibilities, authority, meeting procedures, reporting, and performance evaluation of the company's general manager and senior management. There is no financial data, no mention of financial results, no shareholder meeting materials, no voting results, no audit information, no legal proceedings, no capital or financing updates, no earnings release, no ESG information, no merger or acquisition activity, no director dealings, no dividend notices, no proxy materials, and no regulatory filings or announcements. The document is a governance-related internal policy document describing management roles and procedures. Therefore, it fits best under Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RPA or RNS. Confidence is high due to the clear nature of the document as a governance policy.
2025-10-24 Chinese
开源证券股份有限公司关于江苏四环生物股份有限公司详式权益变动报告书之2025年二季度持续督导意见
Regulatory Filings Classification · 85% confidence The document is a continuous supervision opinion (“持续督导意见”) issued by the financial advisor following a detailed equity change report (“详式权益变动报告书”). It is neither an annual/interim financial statement nor a proxy or earnings announcement, nor a share buyback or dividend notice. This is a compliance/regulatory filing by the securities firm to satisfy obligations under China’s takeover and disclosure rules. It therefore falls into the fallback Regulatory Filings category (RNS).
2025-09-09 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 Half-Year Report Summary' (半年度报告摘要) for Jiangsu Sihuan Biological Co., Ltd. It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, and shareholder information. It also discusses changes in controlling shareholders and risk warnings related to stock delisting risk. The document length is 3226 characters, which is relatively short but contains substantive financial data and analysis for a half-year period. The presence of detailed financial metrics and company operational data indicates this is a financial report for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a certification, but a summary of the half-year report itself. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-26 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 16th meeting of the 10th Board of Directors of Jiangsu Sihuan Bio Co., Ltd. It includes approval of the 2025 semi-annual report and a capital reduction proposal for a subsidiary. The document is relatively short (837 characters) and references the full semi-annual report being available on an external website, indicating it is not the report itself but an announcement of board decisions and related matters. This fits the category of Board/Management Information (MANG), as it reports on board meeting resolutions and management decisions rather than providing the full financial report or detailed data.
2025-08-26 Chinese
江苏四环生物股份有限公司关于全资子公司减资的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding a capital reduction by a wholly-owned subsidiary of the company. It includes details about the subsidiary, the reduction amount, board approval, and financial data of the subsidiary. The document is relatively short (1904 characters) and focuses on a specific capital change event rather than comprehensive financial reporting. It is not a full financial report but an announcement of a capital change. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2025-08-26 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the period January to June 2025. It includes specific financial figures, accounting subjects, and relationships with related parties. The content is financial and operational in nature but does not represent a full interim or annual financial report. It is a specific financial disclosure related to related party transactions and fund usage, which is typically part of regulatory compliance disclosures. The document length is short (1921 characters) and it contains substantive financial data, but it is not a full financial report like an Interim Report (IR) or Annual Report (10-K). It is more aligned with a Regulatory Filing (RNS) as it provides a specific regulatory disclosure on related party transactions and fund occupation without being a full report or announcement of a report publication.
2025-08-26 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.